LONDON, March 13, 2017 /PRNewswire/ -- e this report
to:
- Analyze the role biobanks play in the development of new drugs
for specific disease treatments.
- Learn about the prevailing market size for certain biobank
services available in the general, ever-growing
pharmaceutical/biomedical technology market.
- Identify factors influencing the ever-increasing demand for
biobanks and significant biobank technologies, repositories and
geographies.
Download the full report:
https://www.reportbuyer.com/product/4417134/
Highlights
- The global market for biobanking technologies was valued at
$186.3 billion in 2015. This market
is expected to increase from $198.2
billion in 2016 to $240.2
billion in 2021 at a compound annual growth rate (CAGR) of
3.9% for 2016-2021.
- The private sector of biobanking is expected to grow from
$78.5 billion in 2016 to $93.7 billion in 2021 at a CAGR of 3.6% from 2016
through 2021.
- Population biobanking is expected to grow from $57.8 billion in 2016 to $76.7 billion at a CAGR of 5.8% from 2016 through
2021.
STUDY GOALS AND OBJECTIVES
This is a comprehensive analysis report of the global biobanks
market. It reviews various products in the global biobank markets
together with projected sales and trends in the industry through
2021. The document offers a range of information, spanning general
trends in the industry to detailed analyses of the role biobanks
play in the development of new drugs for specific disease
treatments.
The information offered in this report is valuable to the reader in
quantifying and evaluating the prevailing market size for certain
biobank services available in the general, ever-growing
pharmaceutical/biomedical technology market. Various data sources,
including but not limited to company publications, industry sources
and benchmarks, and other sources, have been used to develop trends
and forecasts in the biobank industry. Other elements discussed in
the paper include: factors influencing the ever-increasing demand
for biobanks and significant biobank technologies, repositories and
geographies. Evaluation of biotech/pharmaceutical industry markets
vs. the government is given a major consideration in the
report.
REASONS FOR DOING THE STUDY
Great opportunities in the biobank industry await companies that
have deployed effective strategies to invest in this ripe market.
As much as this is true, however, the availability of opportunities
marks a company's ability to develop an effective strategy and ends
with the effective execution of the strategy to capture profit from
it.
In the field of developing new drugs and treatments for particular
diseases, the largest opportunities are found in the biobanks
market. Introduction of a resource into the biobank market for
investigating various combined disease therapies is a critical
driver in the pharma/biotech area; this is an element looked into
thoroughly by this research. During the forecast period, 2016 to
2021, this element is expected to make a substantial contribution
to the growth of the industry. Emerging biobank markets based on
particular applications and disease segments are also analyzed in
this report.
Emerging geographies are expected to continually drive growth in
the global markets. This is attributed to the ever-growing
middle-class in emerging countries like Brazil, India, Russia
and China. The critical topics
required for evaluating emerging technologies and players, changing
market dynamics and strategies for accessing particular
geographies, disease segments and emerging markets to enable
resource allocation and effective decision-making are also
addressed in this study.
SCOPE OF REPORT
This report entails forecasted and prevailing biobank products
within the 2016 to 2021 period. Biobanks play a critical role in
the development of new drugs. The document also features new
FDA-approved products in 2015 and 2016, as well as those awaiting
approval within the forecast period. The 2016 figures in this
report are approximated except in cases where reports of exact
results have been released; this is attributed to the timing of
this report's release.
Emerging companies and the leading competitors in the prevailing
global Biobanks industry are analyzed extensively in this report.
The specific product strategies and products of leading drug
manufacturers in the market are analyzed and profiled in the
report. Biotechnology companies that utilize biobanks to develop
new, novel products are also included in the analysis. New products
expected to be introduced in the market within the forecast period
and their manufacturers, in addition to their impact on the
competitive biobank market are discussed in this report.
The competitive market environment is evaluated with a unique
emphasis on the effect of the new technologies and products on the
prevailing patient care standard. Emerging companies and current
leaders in the market are profiled and discussed in detail. Market
figures are founded on the revenue level of the manufacturers and
forecast done in the 2016-dollar
value. Forecast figures exclude inflation. Parameters like the
introduction of new products, forecast sales for prevailing
products, expanded indications for prevailing products and
forecasted changes in the rates of diagnosis, prevalence and
scripting for specific diseases are considered when assessing
trends.
Forecasts featured in this report for the period between 2016 and
2021 are based on disease category, product and company. The study
is organized for an overview of the biobanks market by geography,
company and product. The projections are based on country or
geographic region. For every disease sub-segment, the global market
is evaluated and data provided.
Consumables that do not require prescription from a physician like
over-the-counter (OTC) drugs are not covered in this report. Sales
figures are in U.S. dollars, with each reflecting change in revenue
performance due to currency fluctuations. Variations in local
currencies, however, are not accounted for by the revenue figures.
Unless pointed out, all data on market share in the report are on a
global basis.
INTENDED AUDIENCE
This report is meant for acquisition specialists, product managers,
business planners, investors, licensing strategists, market
research analysts, investor consultants and any other persons
interested in the biobanks market, industry participants, products
and even its future.
The significance of identifying general product opportunities,
trends in the market, M&A opportunities and insights and
emerging geographies that offer defensive moves or sales growth
guidance cannot be overstated in this study for various
constituents, including but not limited to:
- Sales and marketing, corporate strategy, R&D and business
development aspects of companies that are well-established in this
industry shall benefit from this report.
- Emerging biotechnology players in the biobank market must
comprehend particular opportunities for out-licensing, sourced from
biomarker technology or product differentiation aspects in
comparison to leading, emerging and competitive therapies. Market
forecasts can also support investments as long as there is in
existence detailed and thorough market forecast substantiation, as
provided in this report.
- Investment companies analyzing hedged investments or venture
capital candidates gain insights on the risks and opportunities
present in the industry, a specific analysis of the company and a
product.
- Equity analysts have access to detailed forecasts substantiated
through quantitative analysis, spanning the next five years, with
the ability to support further evaluation of company and product
forecasts in the long- and short-term.
ANALYST'S CREDENTIALS
Jackson Highsmith is a life sciences
research consultant with more than 16 years of research experience.
Jackson has been consulting with specialty pharmaceuticals and
large pharmaceutical industry players since 2007. Prior to that, he
worked at a large research consultancy, where he focused on
in-depth research; he also has worked at a large pharmaceutical
company in a wide range of medical therapeutics in early- and
mid-stage drug development.
METHODOLOGY AND INFORMATION SOURCES
Leading industry experts, like industry analysts, company
executives and top medical practitioners, were interviewed through
an in-depth and thorough interviewing process. Various independent
segments experiencing fast growth make up the general biobank
field. The total market opportunity in every segment makes up both
the projected and prevailing markets for completeness reasons.
Every relevant growth area and driving mechanism features a
detailed forecast in each market segment.
Emerging and participating companies in the biobank market like the
National Heart, Lung and Blood Institute and the American Heart
Association were the major sources of information used to develop
this report. Other sources of information include: published
articles in medical journals like Circulation, the American Heart
Journal, Lancet and BioBanks Pharmacology Journal, among others;
Government agencies and World Health Organizations; annual reports;
literature searches; and 10Ks, among others. The U.S. Census Bureau
International database was the major source of estimates on
population data in this report.
Company disclosures held in the public domain or by the government
acted as the major sources of historical and current individual
product revenue figures.
Download the full report:
https://www.reportbuyer.com/product/4417134/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biobanking-technologies-and-global-markets-300422752.html
SOURCE ReportBuyer